Esperion Therapeutics (ESPR) Other Working Capital Changes (2012 - 2026)

Esperion Therapeutics' Other Working Capital Changes history runs 7 years deep, the most recent figure standing at $1.3 million for Q4 2025.

• Quarterly Other Working Capital Changes changed N/A year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.7 million (changed N/A YoY) and the FY2025 annual result came in at $8.7 million, changed N/A from the prior year.
• Other Working Capital Changes was $1.3 million for Q4 2025 at Esperion Therapeutics, up from -$6.4 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $19.7 million in Q2 2025 and bottomed at -$5.3 million in Q2 2023.
• A 5-year average of $2.7 million and a median of $1.9 million in 2022 frame the typical range for Other Working Capital Changes.
• Annual changes were most pronounced in 2021 — Other Working Capital Changes surged 6888.89% — and 2022, when it plunged 338.37%.
• Esperion Therapeutics' Other Working Capital Changes stood at -$3.5 million in 2021, then surged by 84.81% to -$538000.0 in 2022, then surged by 1155.58% to $5.7 million in 2023, then plunged by 169.52% to -$3.9 million in 2024, then surged by 133.0% to $1.3 million in 2025.
• Business Quant data shows ESPR's Other Working Capital Changes at $1.3 million in Q4 2025, -$6.4 million in Q3 2025, and $17.8 million in Q2 2025.